
Yashpal Singh Malik
Deputy Director General (Agricultural Education)Indian Council of Agricultural Research, Headquarters, New Delhi , India

Submitted
2024/04/25First Online
2024/12/26doi
10.18805/IJAR.BF-1807Cite article - Gang Qiu, Yapei Rui, Quanchao Ma, Bingjie Ma, Xun Li. (2024). Break Point of Enrofloxacin for Mycoplasma hyopneumoniae. Indian Journal of Animal Research. 59(5): 818–827. doi: 10.18805/IJAR.BF-1807
Background: There are currently no clinical breakpoints available to facilitate data interpretation and the correlation of MICs with in viv o efficacy. Defining the break point of enrofloxacin for Mycoplasma hyopneumoniae can determine the choice of empirical treatment and targeted therapy, predict the efficacy of drugs against specific animals and analyze treatment failure.
Methods: We determined the breakpoint of M. hyopneumonaie to enrofloxacin by susceptibility testing and pharmocokinetics/pharmacodynamics model.
Result: The pharmacodynamic cutoff value of M. hyopneumoniae against enrofloxacin was 0.25 µg/mL and the clinical break point was 2 µg/mL. After comprehensive weighing, the final sensitivity break point was set at 2 µg/mL.To provide reference for in vitro bacteriostatic test of M. hyopneumonaie against enrofloxacin.To provide the basis for the actual dosage of enrofloxacin in the treatment of mycoplasma pneumonia in pigs.
true
Distinguished scholars and subject experts committed to editorial excellence, scientific integrity and rigorous peer review.
View Full Board